Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beach Regimen in Relapsed/Refractory Acute Myeloid Leukemia
NCT07651475Phase 2Active, not recruiting
- Sponsor
- Liping Dou
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Liping Dou. Primary endpoint: Composite Complete Remission Rate at 1 year. Started Jul 2026; status: active, not recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07651475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07651475.